Literature DB >> 14534547

Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice.

Julie M Jones1, Pinaki Datta, Srinivasa M Srinivasula, Weizhen Ji, Sanjeev Gupta, ZhiJia Zhang, Erika Davies, György Hajnóczky, Thomas L Saunders, Margaret L Van Keuren, Teresa Fernandes-Alnemri, Miriam H Meisler, Emad S Alnemri.   

Abstract

The mouse mutant mnd2 (motor neuron degeneration 2) exhibits muscle wasting, neurodegeneration, involution of the spleen and thymus, and death by 40 days of age. Degeneration of striatal neurons, with astrogliosis and microglia activation, begins at around 3 weeks of age, and other neurons are affected at later stages. Here we have identified the mnd2 mutation as the missense mutation Ser276Cys in the protease domain of the nuclear-encoded mitochondrial serine protease Omi (also known as HtrA2 or Prss25). Protease activity of Omi is greatly reduced in tissues of mnd2 mice but is restored in mice rescued by a bacterial artificial chromosome transgene containing the wild-type Omi gene. Deletion of the PDZ domain partially restores protease activity to the inactive recombinant Omi protein carrying the Ser276Cys mutation, suggesting that the mutation impairs substrate access or binding to the active site pocket. Loss of Omi protease activity increases the susceptibility of mitochondria to induction of the permeability transition, and increases the sensitivity of mouse embryonic fibroblasts to stress-induced cell death. The neurodegeneration and juvenile lethality in mnd2 mice result from this defect in mitochondrial Omi protease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14534547     DOI: 10.1038/nature02052

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  123 in total

1.  Hyperexcitable substantia nigra dopamine neurons in PINK1- and HtrA2/Omi-deficient mice.

Authors:  Matthew W Bishop; Subhojit Chakraborty; Gillian A C Matthews; Antonios Dougalis; Nicholas W Wood; Richard Festenstein; Mark A Ungless
Journal:  J Neurophysiol       Date:  2010-10-06       Impact factor: 2.714

Review 2.  Mitochondrial dynamics and mitophagy in Parkinson's disease: disordered cellular power plant becomes a big deal in a major movement disorder.

Authors:  Yuzuru Imai; Bingwei Lu
Journal:  Curr Opin Neurobiol       Date:  2011-11-01       Impact factor: 6.627

3.  Stability and heterogeneity of expression profiles in lung cancer specimens harvested following surgical resection.

Authors:  Fiona H Blackhall; Melania Pintilie; Dennis A Wigle; Igor Jurisica; Ni Liu; Nikolina Radulovich; Michael R Johnston; Shaf Keshavjee; Ming-Sound Tsao
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

Review 4.  Mitochondria: pharmacological manipulation of cell death.

Authors:  Lisa Bouchier-Hayes; Lydia Lartigue; Donald D Newmeyer
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 5.  Mitochondria: a target for cancer therapy.

Authors:  Jeffrey S Armstrong
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  Quality control of mitochondria: protection against neurodegeneration and ageing.

Authors:  Takashi Tatsuta; Thomas Langer
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

7.  The yeast HtrA orthologue Ynm3 is a protease with chaperone activity that aids survival under heat stress.

Authors:  Nirmala Padmanabhan; Lars Fichtner; Achim Dickmanns; Ralf Ficner; Jörg B Schulz; Gerhard H Braus
Journal:  Mol Biol Cell       Date:  2008-10-22       Impact factor: 4.138

Review 8.  Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's disease.

Authors:  Georgia S Gaki; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2014-02-13       Impact factor: 3.843

Review 9.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

Review 10.  Caspase-independent cell death: leaving the set without the final cut.

Authors:  S W G Tait; D R Green
Journal:  Oncogene       Date:  2008-10-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.